Castillo-Martínez D, Rosas-Barrientos JV, Serrano-López A, Amezcua-Guerra LM

Language: Spanish
References: 50
Page: 10-20
PDF size: 386.28 Kb.

ABSTRACT

Inflammatory bowel disease (IBD) is a term used to describe a heterogeneous group of entities that shared chronic inflammatory infiltration of the gastrointestinal tract. The 2 major types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). UC is limited to the colon and CD can involve any segment of the gastrointestinal tract. The pathophysiology of IBD is under active investigation. The common end pathway is inflammation of the mucosal lining of intestinal tract, causing ulceration, edema, bleeding, and fluid and electrolyte loss. The clinical manifestations of IBD depends on the area of the intestinal tract is involved, but the patients frequently have bloody diarrhea, occasionally with tenesmus. Laboratory studies are used as surrogate markers of inflammation and are of minimal help in establishing the diagnosis. Colonoscopic and histologic findings are the mainstream in the diagnosis. The care of a patient with IBD can be either medical or surgical in nature, or commonly a combination of both.

REFERENCES

1. Rose S, ed. Inflammatory bowel disease. En: Gastrointestinal and Hepatobiliary Pathophysiology. Madison, Conn; Fence Creek Publishing 1998:245-57.

2. Friedman S, Blumberg RS. Inflammatory bowel disease. En: Braunwald E, Fauci AS, Kasper DL (Ed). Harrison’s Principles of Internal Medicine, 15th ed. McGraw-Hill, New York, 2001.

3. Knigge KL. Inflammatory Bowel Disease. Clinical Cornerstone 2002;4.

4. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-5.

5. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.

6. Thompson NP, Driscoll R, Pounder RE, et al. Genetics versus enviroment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95-6.

7. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35:1075-81.

8. Satsangi J, Jewell DP, Bell JI. The genetics of inflammatory bowel disease. Gut 1997;40:572-4.

9. Binder V. Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998;16:351-5.

10. Stokkers PC, Reitsma PH, Tytgat GN, et al. HLA-DR and –DQ haplotypes in inflammatory bowel disease: a meta-analysis. Gut 1999;45:395-401.

11. Kam LY, Targan SR. TNF-alpha antagonists for the treatment of Crohn’s disease. Expert Opin Pharmacother 2000;1:615-22.

12. Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn’s disease is associated with novel polymorphisms in the 5’-flanking region of the tumor necrosis factor gene. Gastroenterology 1999;117:1062-8.

13. Carter MJ, di Giovine FS, Jones S, et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001;48:461-7.

14. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996;379:821-3.

15. The IBD International Genetics Consortium. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am J Hum Genet 2001;68:1165-71.

16. Bonen DK, Ogura Y, Nicolae DL, et al. Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003;124:140-6.

17. Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 2003;37:358-67.

18. Ogura Y, Bonen DK, Inhohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411:603-6.

19. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.

20. Evans JM, McMahon AD, Murray FE, McDevitt DG, McDonald TM. Non-steroidal anti-inflammatory drugs are associated with admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619-22.

21. Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut 1988;29:352-7.

22. Rath CH, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immunol 2001;69:2277-85.

23. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.

24. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996;157:1261-70.

25. Fiocchi C. Inflammatory bowel disease: etiology and patogenesis. Gastroenterology 1998;115:182-205.

26. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.

27. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:318-27.

28. Eggena M, Targan SR, Iwanczyk L, et al. Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol 1996;156:4005-11.

29. Vecchi M, Sinico A, Bianchi MB, et al. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand J Gastroenterol 1998;33:1284-8.

30. Glas J, Torok HP, Vilsmaier F, et al. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion 2002;66:173-7.

31. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn’s disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003;98:2226-31.

32. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000;68:1542-8.

33. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002;123:689-99.

34. Seibold F, Mork H, Tanza S, et al. Pancreatic autoantibodies in Crohn’s disease: a family study. Gut 1997;40:481-4.

35. Joossens S, Colombel JF, Vermeire S, et al. Panel of serologic antibodies in patients with indeterminate colitis. Gastroenterology 2003;124:A323.

36. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol 2002;97:1458-62.

37. McQuaid KR. Diseases of the Colon and Rectum. En: Tierney LM, McPhee SJ, Papadakis MA (Ed). Current Medical Diagnosis & Treatment. 40th Ed. Lange Medical Books/McGraw-Hill 2001. New York, USA.

38. Katz S. Update in Medical Therapy of Ulcerative Colitis. A Practical Approach. J Clin Gastroenterol 2002;34:397-407.

39. Su Ch, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin North Am. 2002:86.

40. Targan SR, Hanauer SB, van Deventer SJ, et al. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.

41. D’Haens G, van Deventer S, van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.

42. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-405.

43. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.

44. D’Haens G, Swijsen C, Norman M, et al. Etanercept (TNF receptor fusion protein, Enbrel) is effective and well tolerated in active refractory Crohn’s disease: results of a single center pilot trial. Gastroenterology 2001;118:A656.

45. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.

46. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999;117:1271-7.

47. Kam AL, Vasiliauskas EA, Abreu MT, et al. Open labeled pilot study of thalidomide as a novel therapy for medically resistant ulcerative colitis. Gastroenterology 2000;118:A582.

48. Amezcua-Guerra LM. Efectos adversos de los agentes biológicos en Artritis Reumatoide. Rev Mex Reumatol 2004;19:201-9.

49. Weiss A, Mayer L. Extraintestinal manifestations of inflammatory bowel disease. En: Allan R, Rodees J, Hanauer S (Eds). Inflammatory Bowel Diseases. 3rd ed. London. Churchill Livingstone 1997:623-32.

50. Meagher A. Ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800.